GLAXF - GlaxoSmithKline plc

Other OTC - Other OTC Delayed price. Currency in USD
19.95
0.00 (0.00%)
As of 9:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close19.95
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume0
Avg. volume2,081
Market cap92.09B
Beta1.12
PE ratio (TTM)39.66
EPS (TTM)0.5
Earnings dateN/A
Dividend & yield1.02 (5.07%)
Ex-dividend date2017-08-10
1y target estN/A
Trade prices are not sourced from all markets
  • Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada
    Zacks19 hours ago

    Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada

    GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.

  • Reuters4 days ago

    GlaxoSmithKline's shingles vaccine gets approval in Canada

    (Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ...

  • The Wall Street Journal6 days ago

    [$$] Ebola Vaccines Show Promise in New Study

    The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...

  • BAE Systems to axe over 1,000 UK jobs amid Typhoon slowdown
    Sky News8 days ago

    BAE Systems to axe over 1,000 UK jobs amid Typhoon slowdown

    BAE Systems (LSE: BA.L - news) , Britain's biggest defence contractor, is to axe more than 1,000 jobs this week in a bitter blow for Britain's manufacturing industry. Sky News has learnt that BAE will announce that many of the job cuts will affect its Warton plant in Preston (Other OTC: PSNP - news) , Lancashire, with the company's new chief executive, Charles Woodburn, also "trimming" its workforce at other locations.

  • May to consult business leaders on Brexit
    Reuters9 days ago

    May to consult business leaders on Brexit

    Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit. Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019.

  • Fool.co.uk10 days ago

    GlaxoSmithKline plc is one of 10 top stocks for a Footsie starter portfolio

    G A Chester's quarterly review of 10 FTSE 100 (INDEXFTSE:UKX) industry giants, including GlaxoSmithKline plc (LON:GSK).

  • Market Realist12 days ago

    Changes in GlaxoSmithKline’s Valuation

    As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x.

  • Reuters - UK Focus12 days ago

    Drug industry gives up legal battle over new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 5 (Reuters) - Britain's pharmaceuticals industry has thrown in the towel in a legal battle over new cost curbs imposed by the state-run health service, after failing to secure a judicial review. Drugmakers argue the curbs, imposed earlier this year, have the potential to cause significant delays for patients waiting for treatment for a range of conditions, including for cancer, heart disease and diabetes. The Association of the British Pharmaceutical Industry (ABPI) said on Thursday, however, that its board had agreed unanimously not to appeal after a High Court judge turned down its review application on Wednesday.

  • Market Realist12 days ago

    Performance of GlaxoSmithKline’s Consumer Healthcare Segment

    GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.

  • Market Realist12 days ago

    Quarterly Performance of GlaxoSmithKline’s Vaccines Segment

    The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.

  • Reuters - UK Focus13 days ago

    Drug industry fails to win judicial review of new UK cost curbs

    LONDON, Oct (Shenzhen: 000069.SZ - news) 4 (Reuters) - Britain's pharmaceuticals industry failed to secure a judicial review of new cost curbs, which mean drugs costing NHS England more than 20 million pounds ($26 mln) annually no longer get automatic funding. The Association of the British Pharmaceutical Industry (ABPI) had sought to challenge the additional hurdle to drug uptake that was implemented by the National Institute for Health and Care Excellence (NICE (Other OTC: NCSYF - news) ) earlier this year. On Wednesday it said it was disappointed the judicial review application had been turned down.

  • Market Realist13 days ago

    Quarterly Performance for GlaxoSmithKline’s HIV Business

    HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq.

  • Market Realist13 days ago

    GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17

    GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.

  • Market Realist14 days ago

    GlaxoSmithKline’s Quarterly Revenues

    GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.

  • Market Realist14 days ago

    GlaxoSmithKline’s Recent 3Q17 Developments

    On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies.

  • Reuters15 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters15 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Reuters - UK Focus15 days ago

    U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline

    Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - A U.S. judge has dismissed a lawsuit by two former corporate investigators who accused GlaxoSmithKline (Amsterdam: GO8.AS - news) Plc (GSK) of misleading them into investigating a whistleblower in China, leading to their arrest amid a bribery scandal involving the drugmaker. U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee. The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China.

  • Fool.co.uk22 days ago

    Why I’d buy GlaxoSmithKline plc for its 5%+ dividend yield today

    Edward Sheldon explains why he sees appeal in GlaxoSmithKline plc's (LON:GSK) 5.4% dividend yield.

  • Reuters - UK Focus27 days ago

    GSK's new triple lung drug beats other modern inhalers in study

    GlaxoSmithKline produced clinical data on Wednesday showing its newly approved three-in-one inhaler reduced life-threatening attacks in chronic obstructive pulmonary disease patients more than other modern ...

  • Fool.co.uk28 days ago

    Why I’d buy this biotechnology star alongside GlaxoSmithKline plc

    This great growth prospect should nicely complement solid dividends from GlaxoSmithKline plc (LON: GSK).

  • Reuters - UK Focus28 days ago

    Former GSK CEO and ex-R&D boss move to biotech venture firms

    GlaxoSmithKline's former chief executive Andrew Witty and its one-time research head Moncef Slaoui both picked up new jobs in the biotech venture capital sector on Tuesday, following a route favoured by ...

  • Reuters - UK Focus28 days ago

    GlaxoSmithKline breathes easier as U.S. approves triple lung drug

    U.S. regulators have approved GlaxoSmithKline (Other OTC: GLAXF - news) 's three-in-one inhaler for chronic lung disease, a key new product for the group as it strives to keep its lead in respiratory medicine despite falling sales of the older drug Advair. Trelegy Ellipta is the first once-daily triple medicine for chronic obstructive pulmonary disease (COPD), putting Britain's biggest drugmaker ahead of rivals such as AstraZeneca (Swiss: AZN.SW - news) and Novartis (IOB: 0QLR.IL - news) .

  • Reuters - UK Focus29 days ago

    U.S. FDA approves GSK's three-in-one drug inhaler for COPD

    GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease . GSK's once-daily ...

  • Business Wire29 days ago

    Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US

    LONDON--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes